Sales: $3.3 billion
Note: $3.3 billion for oral care products. Corporate sales: $43.1 billion
Emma Walmsley, chief executive officer; Iain Mackay, chief financial officer; Dr. Hal Barron, chief scientific officer and president, R&D; Brian McNamara, chief executive officer, consumer healthcare; Karenann Terrell, chief digital and technology officer
Oral care: Sensodyne, Polident/Corega, Parodontax, Biotene and Aquafresh
Comments: GlaxoSmithKline is on the front line in the fight against COVID-19, but the company also has a thriving oral care business. Last year, oral care sales rose 7%. Sensodyne posted double-digit, broad-based growth, with strong performance in the US and India benefitting from new product launches. Gum health also posted double-digit gains, while denture care grew mid-single digits.
Last year, GSK finalized a deal with Pfizer to combine their two consumer healthcare businesses into a joint venture. As previously announced, GSK intends to demerge the JV from the company within three years and to list the GSK Consumer Healthcare business on the UK equity market.
“The completion of the joint venture with Pfizer marks the beginning of the next phase of our transformation of GSK,” said Emma Walmsley, chief executive officer, GSK and chair of the joint venture. “This is an important moment for the group, laying the foundation for two great companies, one in pharmaceuticals and vaccines and one in consumer health.”
For the first quarter, corporate sales surged 19% and consumer healthcare sales jumped 46%—due primarily to the inclusion of the Pfizer consumer healthcare portfolio. Oral care sales rose 11% in the quarter, helped by gains from Sensodyne, and gum and denture care.